Damien Driot1,2, Emilie Jouanjus2,3, Stéphane Oustric1,2, Julie Dupouy1,2, Maryse Lapeyre-Mestre2,3,4. 1. Département universitaire de médecine générale, Faculté de Médecine, Université de Toulouse, France. 2. Unité Mixte de Recherche, 1027 Inserm-Université, Pharmacoépidémiologie, Université de Toulouse, France. 3. Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP), Service de Pharmacologie Médicale et Clinique, CHU de Toulouse, France. 4. Centre d'Investigation Clinique, 1436 Inserm CHU, CHU de Toulouse, France.
Abstract
AIMS: The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population. METHODS: New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse. RESULTS: Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (P < 0.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29-1.69]), age (HR[18-45] versus > 70 years 1.98 [1.70-2.31] and HR[58-70] versus > 70 years 1.25 [1.06-1.47]), multiple prescribers (HR2 or 3 versus 1 prescriber 1.29 [1.15-1.45]; HR4 or more versus 1 prescriber 1.54 [1.30-1.83]), cancer (1.28 [1.11-1.47]), multiple sclerosis (1.53 [1.07-2.18]), neuropathy (1.85 [1.19-2.89]), depression (1.26 [1.07-1.49]) and methadone (2.61 [1.16-5.84]). After this first episode of drug misuse, 11.6% of gabapentin and 10.7% of pregabalin misusers developed a primary addiction. CONCLUSION: In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.
AIMS: The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population. METHODS: New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse. RESULTS: Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (P < 0.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29-1.69]), age (HR[18-45] versus > 70 years 1.98 [1.70-2.31] and HR[58-70] versus > 70 years 1.25 [1.06-1.47]), multiple prescribers (HR2 or 3 versus 1 prescriber 1.29 [1.15-1.45]; HR4 or more versus 1 prescriber 1.54 [1.30-1.83]), cancer (1.28 [1.11-1.47]), multiple sclerosis (1.53 [1.07-2.18]), neuropathy (1.85 [1.19-2.89]), depression (1.26 [1.07-1.49]) and methadone (2.61 [1.16-5.84]). After this first episode of drug misuse, 11.6% of gabapentin and 10.7% of pregabalin misusers developed a primary addiction. CONCLUSION: In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.
Authors: V Pauly; V Pradel; L Pourcel; S Nordmann; E Frauger; M Lapeyre-Mestre; J Micallef; X Thirion Journal: Drug Alcohol Depend Date: 2012-04-03 Impact factor: 4.492
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham Journal: Clin Drug Investig Date: 2021-02-12 Impact factor: 2.859
Authors: Kirk E Evoy; Sarvnaz Sadrameli; Jillian Contreras; Jordan R Covvey; Alyssa M Peckham; Megan D Morrison Journal: Drugs Date: 2021-01 Impact factor: 9.546
Authors: Yusuf S Althobaiti; Amal Alghorabi; Fahad S Alshehri; Bandar Baothman; Atiah H Almalki; Hashem O Alsaab; Walaa Alsanie; Ahmed Gaber; Hussam Almalki; Abdulrahman S Alghamdi; Ahmad Basfer; Sultan Althobaiti; Ana Maria Gregio Hardy; Zahoor A Shah Journal: Sci Rep Date: 2020-06-26 Impact factor: 4.379
Authors: Jacoline J van den Driest; Dieuwke Schiphof; Marcel de Wilde; Patrick J E Bindels; Johan van der Lei; Sita M A Bierma-Zeinstra Journal: Rheumatology (Oxford) Date: 2021-05-14 Impact factor: 7.580